SAB Biotherapeutics Stock Price, News & Analysis (NASDAQ:SABS) $0.91 -0.03 (-3.19%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$0.88▼$0.9750-Day Range$0.47▼$1.0152-Week Range$0.37▼$1.45Volume197,478 shsAverage Volume408,146 shsMarket Capitalization$47.61 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media SAB Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside9.9% Upside$1.00 Price TargetShort InterestHealthy0.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 6 Articles This WeekInsider TradingAcquiring Shares$14,290 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.46) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector865th out of 952 stocksBiological Products, Except Diagnostic Industry144th out of 155 stocks 1.3 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, SAB Biotherapeutics has a forecasted upside of 9.9% from its current price of $0.91.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.61% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in SAB Biotherapeutics has recently decreased by 12.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 3.1 News and Social Media Coverage News SentimentSAB Biotherapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for SABS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows2 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,290.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.18% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.82% of the stock of SAB Biotherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($0.46) to ($0.30) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SAB Biotherapeutics Stock (NASDAQ:SABS)SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.Read More SABS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Stock News HeadlinesDecember 1, 2023 | msn.comVerifyMe And 3 Other Stocks Under $2 Insiders Are BuyingNovember 29, 2023 | finance.yahoo.comSAB Biotherapeutics Starts Human Clinical Trial of Diabetes TreatmentDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 29, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In AustraliaNovember 29, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNovember 20, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNovember 20, 2023 | finance.yahoo.comSAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNovember 14, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 14, 2023 | msn.comSAB Biotherapeutics GAAP EPS of -$0.10November 14, 2023 | finance.yahoo.comSAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in FinancingNovember 14, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNovember 14, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNovember 9, 2023 | finance.yahoo.comSAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNovember 6, 2023 | msn.comSAB Biotherapeutics files to sell 412.7M units to noteholdersOctober 24, 2023 | finance.yahoo.comSAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerOctober 19, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: SAB Biotherapeutics (SABS), Elevance Health (ELV)October 19, 2023 | finance.yahoo.comSAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesOctober 6, 2023 | markets.businessinsider.comSAB Biotherapeutics’ Financial Stability and Potential Growth: A Comprehensive Analysis of Edward White’s Buy RatingOctober 6, 2023 | markets.businessinsider.comSecured Financing and Promising Clinical Developments Bolster Buy Rating for SAB BiotherapeuticsOctober 5, 2023 | finance.yahoo.comSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsOctober 5, 2023 | finance.yahoo.comSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsOctober 3, 2023 | finance.yahoo.comSAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes TreatmentOctober 2, 2023 | finance.yahoo.comEXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes CandidateOctober 2, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesAugust 22, 2023 | seekingalpha.comSAB Biotherapeutics GAAP EPS of -$0.14August 22, 2023 | markets.businessinsider.comSAB Biotherapeutics (SABS) Gets a Buy from Chardan CapitalSee More Headlines Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+9.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,740,000.00 Net Margins-664.68% Pretax Margin-664.04% Return on Equity-120.36% Return on Assets-69.17% Debt Debt-to-Equity Ratio0.23 Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$23.90 million Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book1.26Miscellaneous Outstanding Shares52,320,000Free Float36,006,000Market Cap$47.61 million OptionableNot Optionable Beta1.03 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Samuel J. Reich (Age 48)Executive Chairman Comp: $376.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, President, CEO & Director Comp: $430.62kMs. Christine E. Hamilton M.B.A. (Age 67)Co-Founder & Independent Director Comp: $25kDr. Alexandra Kropotova M.B.A. (Age 50)M.D., Executive VP & Chief Medical Officer Comp: $486.96kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverMr. Michael George King Jr. (Age 62)Chief Financial Officer Dr. Christoph Bausch M.B.A. (Age 52)Ph.D., Executive VP & COO Mr. Russell P. Beyer C.M.A. (Age 68)M.B.A., Senior Advisor Dr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsSangamo TherapeuticsNASDAQ:SGMOCurisNASDAQ:CRISAcorda TherapeuticsNASDAQ:ACORPrecision BioSciencesNASDAQ:DTILOKYO PharmaNASDAQ:OKYOView All CompetitorsInsiders & InstitutionsMichael KingBought 5,000 shares on 11/30/2023Total: $4,500.00 ($0.90/share)Samuel J ReichBought 11,000 shares on 11/29/2023Total: $9,790.00 ($0.89/share)Pathstone Family Office LLCBought 506,513 shares on 11/8/2023Ownership: 0.968%View All Insider TransactionsView All Institutional Transactions SABS Stock Analysis - Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SABS shares. View SABS analyst ratings or view top-rated stocks. What is SAB Biotherapeutics' stock price target for 2024? 2 brokerages have issued twelve-month price targets for SAB Biotherapeutics' shares. Their SABS share price targets range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts. How have SABS shares performed in 2023? SAB Biotherapeutics' stock was trading at $0.5899 on January 1st, 2023. Since then, SABS shares have increased by 54.3% and is now trading at $0.91. View the best growth stocks for 2023 here. When is SAB Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our SABS earnings forecast. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The firm had revenue of $1.27 million for the quarter. SAB Biotherapeutics had a negative net margin of 664.68% and a negative trailing twelve-month return on equity of 120.36%. Who are SAB Biotherapeutics' major shareholders? SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pathstone Family Office LLC (0.97%). Insiders that own company stock include Christine E Hamilton, Michael King and Samuel J Reich. View institutional ownership trends. How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SABS) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.